The Role of the 21-Gene Recurrence Score® Assay in Hormone Receptor-Positive, Node-Positive Breast Cancer: The Canadian Experience
M Yordanova, S Hassan - Current Oncology, 2022 - mdpi.com
The management of patients with hormone receptor-positive breast cancer has changed
dramatically with use of the 21-gene Recurrence Score®(RS) Assay. While the utility of the …
dramatically with use of the 21-gene Recurrence Score®(RS) Assay. While the utility of the …
Tumor grade and progesterone receptor status in predicting benefit of chemotherapy in high genomic risk breast cancer
K Liu, GP Chen, XQ Chen, SG Wu - Expert Review of Anticancer …, 2024 - Taylor & Francis
Background Not all eligible breast cancer (BC) patients could afford the expensive test of 21-
gene recurrence score (RS) assay. This study aimed to identify clinicopathological factors …
gene recurrence score (RS) assay. This study aimed to identify clinicopathological factors …
Impact of the 21-gene expression assay on treatment decisions and clinical outcomes in breast cancer with one to three positive lymph nodes
GQ Li, SJ Xie, SG Wu, ZY He - Frontiers in Endocrinology, 2023 - frontiersin.org
Background To assess the practice patterns of the recurrence score (RS) based on the 21-
gene expression assay on adjuvant chemotherapy recommendations and survival outcomes …
gene expression assay on adjuvant chemotherapy recommendations and survival outcomes …
[HTML][HTML] Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center
J Loggie, PJ Barnes, MD Carter, D Rayson… - The Breast, 2024 - Elsevier
Purpose It remains unclear whether patients with HER2-negative, low-estrogen receptor (ER-
low)-positive early breast cancer (BC) benefit from Oncotype DX®(ODX) testing. Methods …
low)-positive early breast cancer (BC) benefit from Oncotype DX®(ODX) testing. Methods …
Identifying Clinicopathological Factors Associated with Oncotype DX® 21-Gene Recurrence Score: A Real-World Retrospective Cohort Study of Breast Cancer …
S Gagnet, C Diorio, L Provencher… - Journal of Personalized …, 2021 - mdpi.com
Gene expression profiling tests such as the Oncotype DX (ODX) 21-gene recurrence score
(RS) assay is increasingly used in clinical practice to predict the risk of recurrence and …
(RS) assay is increasingly used in clinical practice to predict the risk of recurrence and …
[HTML][HTML] Oncotype DX in Breast Cancer Management: Insights and Outcomes From the United Arab Emirates
MA Ameri, NM Shanbhag, AB Sumaida, J Ansari… - Cureus, 2024 - ncbi.nlm.nih.gov
Materials and methods A retrospective cohort study was conducted on 95 breast cancer
patients diagnosed at Tawam Hospital between 2013 and 2017 who underwent Oncotype …
patients diagnosed at Tawam Hospital between 2013 and 2017 who underwent Oncotype …